Dialysis may be near—but the capacity to walk is still worth fighting for

October 30, 2026 PubMed publication record · Small parallel-group randomized clinical trial · Primary source

For someone with stage 4 or 5 kidney disease, the ability to walk farther can mean more than an improved laboratory value. A new randomized trial tested a 12-week home-based exercise program delivered with telehealth support to adults who had not yet started dialysis. It is a small study with an unusually tangible endpoint.

Fifty-four patients were randomized and 51 completed analysis. The intervention group gained an average 29.41 meters on the six-minute walk test, while usual-care controls declined by 19.27 meters—roughly a 48.7-meter difference in change, with P<0.001. The participants also reported improvements in fatigue, mood, sleep and quality of life, with favorable changes on functional and sarcopenia-risk measures. Forty percent used the web platform; sixty percent received video-based support.

The program was short, the sample was small and the complete-case analysis can overstate certainty if attrition was related to outcome. We do not yet know whether gains last, prevent falls or affect hospitalizations. Nevertheless, walking distance is meaningful function, and the remote delivery model is transferable as a research question.

Clinical reading: Promising adjunct in selected patients with advanced CKD after exercise clearance and individualized safety assessment.